Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results